Third-Generation Salvage Cryotherapy for Radiorecurrent Prostate Cancer: A Centre’s Experience
Urologia Internationalis, 03/29/2012
The relatively high rates of biochemical response support the use of cryotherapy as a salvage procedure for radiorecurrent prostate cancer.
Between February 2006 and August 2008, 19 patients underwent salvage cryotherapy for radiorecurrent prostate cancer.
Post-radiotherapy recurrence was confirmed by prostatic biopsy.
The ‘Phoenix definition’ was used to define biochemical failure after salvage cryotherapy.
The mean age at cryotherapy was 69.2 years and the mean time from radiotherapy to cryotherapy was 72.3 months.
Patient characteristics prior to cryotherapy included a mean PSA level of 6.84 ng/ml and a median Gleason score of 7.
The mean post-cryotherapy follow-up was 33.3 months.
The 2-year biochemical disease-free survival rate was 58%.
The median post-cryotherapy PSA nadir was 0.20 ng/ml (range 0.005–8.260).
There were no procedure-related or cancer-related deaths.